Sanofi SAN -0.13% agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in its ...

French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).

Sanofi has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said on ...

Sanofi last week closed its purchase of an early-stage immunology drug candidate from Dren Bio for up to $1.9 billion and in May agreed to acquire Vigil Neuroscience for about $470 million, adding ...